Cytotoxic T cell (CTL) assay with Tecentriq (anti-PDL1) – IMMUNE 3D

Description

The cytotoxic T Lymphocyte (CTL) response is recognized as perhaps the most relevant functional measure that reflects cell-mediated acquired immune defense against viral infections and cancer. The CTL responses can evaluate effective antigen presentation by tumors and is a key assessment in how well a drug candidate enhances CTL responses in eradicating or killing tumors. IMMUNE 3D® is a physiologically relevant platform that is designed to capture the immune-tumor interactions in the presence of tumor environment cells.  This assay utilizes our proprietary HLA-matched CTL and tumor cell lines and is run in a 24 well format.

What is the assay setup?

1. Co-culture tumor and CTL for 6 days in the presence of drug candidate
2. After 6 days harvest the supernatants
3. Measure cytokine release and tumor lysis

What are the study arms?

1. CTL + Tumor+ Tecentriq (anti-PDL1)
2. CTL + Tumor+ <drug candidate (per dose)>
3. CTL + Tumor
4. CTL + Tumor + DMSO
5. CTL
6. Tumor

How many doses are included?

The assay is run in a 24 well plate and can accommodate up to 7 doses of the drug candidate. Each dose is a well. Each dose is run in duplicates (2 times)

What readouts are included in the price?

• Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
• Lactate dehyrdogenase (LDH)  for tumor lysis
• Assay setup and methods used
• Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.